Valneva Selects CliniOps as the Technology Partner for Multiple Post-Marketing Studies to Support the IXCHIQ Chikungunya Vaccination Program in Brazil

Valneva SE (VALN) has selected CliniOps as its technology partner for post-marketing surveillance (PMS) studies of its IXCHIQ chikungunya vaccine. CliniOps' unified platform, featuring electronic data capture and remote monitoring capabilities, will support multiple studies, including pregnancy surveillance, a safety cohort study, and a serosurvey study, to assess the vaccine's safety and effectiveness in real-world settings across various locations. The collaboration aims to enhance the efficiency and quality of clinical processes, addressing the growing demand for tech-enabled clinical trials in public health initiatives.

Analysis

Valneva SE (VALN) has selected CliniOps, Inc. as its technology partner for multiple critical Post-Marketing Surveillance (PMS) studies for its IXCHIQ® chikungunya virus (CHIKV) vaccine, a development assigned a strongly positive sentiment score of 0.8. These PMS studies are designed to assess the real-world safety and efficacy of IXCHIQ® and include a pregnancy surveillance study involving approximately 100 women, a safety cohort study with 5,000 participants to monitor Adverse Events of Special Interest (AESIs) and confirmed CHIKV infections post-vaccination, and a serosurvey study of 5,000 individuals to determine pre-exposure CHIKV prevalence. CliniOps will provide its unified technology platform, incorporating electronic data capture (EDC), eConsent, and ePRO, along with essential offline data collection capabilities via mobile tablets, crucial for operations in areas with limited connectivity, such as Brazil, which reported 71,578 CHIKV cases by March 2025. Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, indicated this collaboration supports the continued evaluation of IXCHIQ®, fulfills post-marketing surveillance requirements, and aligns with Valneva’s strategic adoption of innovative technologies to improve the efficiency, cost-effectiveness, and quality of clinical processes. The engagement, also involving Valneva's CRO partner P-95 and Brazil's Instituto Butantan, reflects the increasing global demand for technologically advanced solutions in clinical trials, particularly for significant public health initiatives.

Key Decisions for Investors

• This partnership represents a key operational step for Valneva in advancing its IXCHIQ® vaccine program, fulfilling regulatory commitments, and gathering crucial real-world evidence which may de-risk its commercial profile.
• Investors should closely monitor the progression and subsequent data readouts from these extensive PMS studies, as positive outcomes on safety and effectiveness could bolster IXCHIQ®'s market positioning and adoption, especially given the significant ongoing Chikungunya outbreaks.
• The strong positive sentiment (0.75 for VALN) associated with this news is encouraging; however, the moderate market impact score of 0.4 suggests that while this is a favorable development, its substantial contribution to Valneva's valuation will likely be contingent upon the successful execution and conclusive results of these multi-year surveillance efforts.